Has Hector Martinez Forna, MD received payments from drug or device companies?

Yes. Drug and device makers reported $18,508 in general payments to Hector Martinez Forna, MD across 27 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Hector Martinez Forna, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Hector Martinez Forna, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Hector Martinez Forna, MD

Internal Medicine · Ponce, PRNPI 1164476982

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,600 of the $18,508 with a category attached, or 62.7%. Abbott accounts for 95.1% of it on its own, with 6 other manufacturers making up the rest. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,508in general payments, 2019–2025

Across 27 payments — averaging $685.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$18K
Boston Scientific$691
GSK$120
Medtronic$32
Johnson & Johnson$23
E.r. Squibb & Sons, L.L.C.$21
plus $16 from 1 others

What the payments were for

Consulting fees$11,60063%
Speaking & faculty fees$6,00032%
Travel & lodging$4492%
Food & beverage$4592%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	18	$17,605
Boston Scientific	4	$691
GSK	1	$120
Medtronic	1	$32
Johnson & Johnson	1	$23
E.r. Squibb & Sons, L.L.C.	1	$21
AstraZeneca	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,508 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$8,360

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	74	$50,208
JanumetSitagliptin Phos/Metformin Hcl	39	$24,882
XareltoRivaroxaban	34	$19,456
EntrestoSacubitril/Valsartan	27	$18,814
SynthroidLevothyroxine Sodium	282	$18,065
JardianceEmpagliflozin	27	$16,268
FarxigaDapagliflozin Propanediol	23	$13,655
TradjentaLinagliptin	23	$12,804
BrilintaTicagrelor	19	$9,476
JanuviaSitagliptin Phosphate	15	$8,699
MyrbetriqMirabegron	14	$7,402
Atorvastatin Calcium	862	$7,224
Verapamil SrVerapamil Hcl	27	$6,213
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm	52	$5,969
Losartan Potassium	543	$5,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AstraZenecaFarxiga, Brilinta	$16	$23,13142 claims
Johnson & JohnsonXarelto	$23	$19,45634 claims
GSKBreo Ellipta	$120	$4,51011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Ponce

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →